KRP-N118 License Agreement and Acquisition of Exclusive Rights in Japan and Asia
First written in FY2018. 1 of 4 entries say "Advanced", first in FY2019-Q2. Latest entry: FY2020-Q3.
No other company in this theme has enough history to compare yet.
- FY2020-Q3DroppedAnnual report
「We decided to discontinue development of the compound and terminate the contractual relationship with the company concerning the compound.」
For KRP-N118, discontinuation of development and termination of the licensing relationship with Sanwa Kagaku Kenkyusho were decided. - FY2019Cited as achievedAnnual report
「In August of the same year, we began a late-stage Phase II clinical trial of KRP-N118, a treatment for nocturia associated with nocturnal polyuria.」
The start of the late-stage Phase II clinical trial of KRP-N118 was cited as the year's development milestone. - FY2019-Q2AdvancedAnnual report
「We began a late-stage Phase II clinical trial in August for KRP-N118, a treatment for nocturia associated with nocturnal polyuria.」
For KRP-N118, for which exclusive rights in Japan and Asia had been acquired, a late-stage Phase II clinical trial began in August 2018. - FY2018First statedAnnual report
「In March 2018, KYORIN Pharmaceutical Co.,Ltd. entered into a license agreement with Sanwa Kagaku Kenkyusho Co., Ltd. for KRP-N118 (SK-1404), a treatment for nocturia associated with nocturnal polyuria, developed by that company, and acquired exclusive development and marketing rights in Japan and Asia, including Hong Kong, Taiwan and the 10 ASEAN countries.」
Exclusive development and marketing rights in Japan and Asia were acquired for KRP-N118 to expand the urology pipeline.